# Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria

> **NCT04833855** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 183 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **BIOLOGICAL:** Tezepelumab Dose 1
- **BIOLOGICAL:** Tezepelumab Dose 2
- **BIOLOGICAL:** Omalizumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04833855
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-15
- **Primary completion:** 2022-12-20
- **Final completion:** 2023-04-13
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04833855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04833855, "Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04833855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*